| Drug Type TCR-T Cell therapy | 
| Synonyms Super TCR-T EBV ENBA1 (Fanen Bio) | 
| Target | 
| Action inhibitors | 
| Mechanism EBNA1 inhibitors(Epstein-Barr nuclear antigen 1 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Preclinical | China  | 17 Aug 2024 | 





